An Open-Label Study to Assess the Effects of VMX-C001 in Combination with an Oral FXa DOAC on the Efficacy of Unfractionated Heparin in Healthy Subjects.

1. Men and women of any ethnic origin aged between 18 and 49 years of age,
inclusive, at the time of Screening.
2. Male subjects must be willing to use appropriate contraception, such as a
condom, and to refrain from sperm donation during the study and until 90 days
after VMX-C001 administration.
3. Women of child-bearing potential must agree not to attempt to become
pregnant and to use a highly effective form of birth control during the study
and for 180 days after study drug administration when their sexual partner has
not been vasectomized. Highly effective forms of birth control entail the use
of combined (estrogen- and progestogen-containing) or progestogen-only hormonal
contraception associated with inhibition of ovulation, an intrauterine device
(IUD), an intrauterine hormone-releasing system (IUS) or abstinence.
4. Postmenopausal women must have had >=12 months of spontaneous amenorrhea
(with documented follicle-stimulating hormone (FSH) >=30 mIU/mL).

1. The subject has been administered VMX-C001 before.
2. The subject has taken piroxicam in the 2 weeks prior to Day 1.
3. The subject has taken any non-aspirin, non-piroxicam NSAID in the week prior
to Day 1.
4. The subject requires or has taken during the month prior to Day 1, vitamin K
for therapeutic reasons. Vitamin K not taken for therapeutic purposes is
acceptable throughout the study, e.g. as part of a multivitamin supplement.
5. The subject is receiving or requires, for any cause, any anticoagulant or
antiplatelet therapy including warfarin, clopidogrel or aspirin or any other
anticoagulant or antiplatelet agent or has used these therapies in the month
prior to Day 1.